title: Non-Hodgkin's lymphoma of the testis: a retrospective study of 84 patients treated in the French anticancer centres.
abstract: Primary non-Hodgkin's lymphoma of the testicle is rare. We analysed cases treated in French anticancer centres from 1969 to 1995. All cases were reviewed and classified according to the R.E.A.L. Classification. Eighty-four cases were included in this study. The median age was 67 years (17-85). Disease was classified as stages I in 42 cases, stages II in 19 and stages III-IV in 23. Diffuse large B-cell lymphoma was diagnosed in 75% of cases. Treatment included orchidectomy and radiotherapy and/or chemotherapy. A complete response was obtained in 72.6% of the patient population and in 100%, 68% and 33% of stage I, II and III-IV disease respectively. Recurrence occurred in 32 cases and the most frequent site was the central nervous system: six of these patients presented stage I disease. Median overall survival was 32 months for the entire population, 52 months for stage I, 32 months for stage II, and 12 months for stage III-IV cases (P < 0.0001). Among patients presenting stage I disease, no difference was found between those treated with combined surgery and chemotherapy or surgery followed or not followed by radiotherapy. This study confirms that non-Hodgkin's lymphoma of the testicle carries a poor prognosis. Systemic adjuvant chemotherapy should be discussed because of the high recurrence rate. Inclusion of these cases in large co-operative prospective studies is recommended.
authors.affiliation: Radiation Therapy Group of the Federation of Cancer Centers, Paris, France.
authors.forename: J L
authors.initials: JL
authors.lastname: Lagrange
authors.forename: A
authors.initials: A
authors.lastname: Ramaioli
authors.forename: C H
authors.initials: CH
authors.lastname: Theodore
authors.forename: M J
authors.initials: MJ
authors.lastname: Terrier-Lacombe
authors.forename: V
authors.initials: V
authors.lastname: Beckendorf
authors.forename: P
authors.initials: P
authors.lastname: Biron
authors.forename: C H
authors.initials: CH
authors.lastname: Chevreau
authors.forename: P
authors.initials: P
authors.lastname: Chinet-Charrot
authors.forename: J
authors.initials: J
authors.lastname: Dumont
authors.forename: A
authors.initials: A
authors.lastname: Delobel-Deroide
authors.forename: J
authors.initials: J
authors.lastname: D'Anjou
authors.forename: C
authors.initials: C
authors.lastname: Chassagne
authors.forename: R M
authors.initials: RM
authors.lastname: Parache
authors.forename: J M
authors.initials: JM
authors.lastname: Karsenty
authors.forename: J
authors.initials: J
authors.lastname: Mercier
authors.forename: J P
authors.initials: JP
authors.lastname: Droz
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000473:pathology* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D009919:Orchiectomy; D011379:Prognosis; D011878:Radiotherapy; D012189:Retrospective Studies; D016019:Survival Analysis; D013736:Testicular Neoplasms / Q000473:pathology* / Q000628:therapy*